Get the Stockscreener App
1.74
1.69%
-0.03
Io Biotech Inc stock is traded at $1.74, with a volume of 1.45M.
It is down -1.69% in the last 24 hours and down -10.77% over the past month.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
See More
Previous Close:
$1.77
Open:
$1.76
24h Volume:
1.45M
Relative Volume:
0.53
Market Cap:
$114.63M
Revenue:
-
Net Income/Loss:
$-86.08M
P/E Ratio:
-0.8065
EPS:
-2.1574
Net Cash Flow:
$-72.06M
1W Performance:
-19.44%
1M Performance:
-10.77%
6M Performance:
+58.18%
1Y Performance:
+8.75%
1-Day Range:
$1.72
$1.876
1-Week Range:
$1.72
$2.79
52-Week Range:
$0.66
$2.79
Io Biotech Inc Stock (IOBT) Company Profile
Name
Io Biotech Inc
Sector
Industry
Phone
(457) 070-2980
Address
OLE MAALOES VEH 3, COPENHAGEN
Compare IOBT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
1.74 | 137.69M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Io Biotech Inc Stock (IOBT) Latest News
AI Tools Suggest IO Biotech Inc. May Outperform This WeekJuly 2025 Trade Ideas & Weekly High Momentum Picks - classian.co.kr
How to use a screener to detect IO Biotech Inc. breakouts2025 Market Overview & Daily Oversold Bounce Ideas - Newser
Short interest data insights for IO Biotech Inc.Weekly Investment Report & Entry Point Strategy Guides - Newser
Can IO Biotech Inc. recover in the next quarter2025 Market Overview & AI Enhanced Execution Alerts - Newser
What to expect from IO Biotech Inc. in the next 30 daysWeekly Profit Summary & Real-Time Buy Signal Alerts - Newser
Why IO Biotech Inc. stock attracts strong analyst attentionTrade Exit Report & AI Powered Market Trend Analysis - Newser
Analyzing net buyer seller activity in IO Biotech Inc.Earnings Miss & Technical Entry and Exit Alerts - Newser
Technical Models Detect Momentum Build in IO Biotech Inc.July 2025 Institutional & Precise Swing Trade Entry Alerts - beatles.ru
Using fundamentals and technicals on IO Biotech Inc.2025 Key Highlights & High Conviction Investment Ideas - Newser
How to integrate IO Biotech Inc. into portfolio analysis toolsTrade Ideas & Technical Pattern Based Signals - Newser
Using data filters to optimize entry into IO Biotech Inc.2025 Short Interest & Community Consensus Picks - Newser
IO Biotech Reports Q2 2025 Financial Results - TipRanks
What high frequency data says about IO Biotech Inc.Portfolio Risk Summary & Daily Volume Surge Signals - Newser
IOBT.O Surges 18.75% on Strong Volume — But No Technical Signals Triggered — What’s the Real Driver? - AInvest
Growth or Bubble? IO Biotech’s Recent Surge - StocksToTrade
Combining machine learning predictions for IO Biotech Inc.July 2025 Analyst Calls & Free Accurate Trade Setup Notifications - Newser
IO Biotech Stock Rises Amid Promising Cancer Vaccine Results - timothysykes.com
IO Biotech Reports Q2 2025 Financial Results: Net Loss of $26.2 Million, $28.1 Million in Cash Reserves, and €12.5 Million EIB Loan for Q1 2026 Operations. - AInvest
IO Biotech's Cylembio Shows Promise Despite Missed Endpoint, Analyst Maintains Buy Rating - AInvest
What makes IO Biotech Inc. stock price move sharplyWeekly Stock Analysis & Free Community Supported Trade Ideas - Newser
Strategies to average down on IO Biotech Inc.Share Buyback & Low Drawdown Momentum Ideas - Newser
How sensitive is IO Biotech Inc. to inflationJuly 2025 Setups & Accurate Entry/Exit Alerts - mustnews.co.kr
IO Biotech's 48% Intraday Surge: Clinical Catalysts or Volatility Play? - AInvest
RSI Reset May Fuel Rebound in IO Biotech Inc.2025 Performance Recap & Accurate Intraday Trading Signals - beatles.ru
IO Biotech's 67.57% Intraday Surge: A Volatile Rally Amid Clinical Optimism and Sector Uncertainty - AInvest
IO Biotech’s Experimental Vaccine Shakes Market - StocksToTrade
Is IO Biotech’s Stock Soaring Too High? - timothysykes.com
Is There Enough Volume to Lift IO Biotech Inc.July 2025 Levels & Technical Pattern Based Buy Signals - newsyoung.net
Why Did IO Biotech Stock Soar 10.94%? - AInvest
IO Biotech’s Cylembio Shows Promise Despite Missed Endpoint, Buy Rating Affirmed - TipRanks
Io Biotech shares rise 16.41% premarket after reporting clinical improvement in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA®. - AInvest
Published on: 2025-08-15 23:31:26 - newsyoung.net
Trendlines Converge — Decision Point for IO Biotech Inc.Jobs Report & Free Weekly Chart Analysis and Trade Guides - beatles.ru
IO Biotech Posts Wider Loss in Q2, Misses Primary Endpoint in Phase 3 Trial for Cylembio in Advanced Melanoma - AInvest
Io Biotech Posts Wider Loss in Q2 - Nasdaq
IO Biotech's Earnings Miss and Path to Recovery: Assessing Long-Term Value Amid Short-Term Setbacks - AInvest
IO Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
IO Biotech's Melanoma Vaccine Trial Falls Short of Statistical Goals Despite Clinical Benefits - Stock Titan
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 - Cantech Letter
Io Biotech, Inc. shares rise 1.53% premarket after Cantor Fitzgerald adjusts Bristol-Myers Squibb price target. - AInvest
Published on: 2025-08-14 10:10:31 - beatles.ru
IO Biotech says cancer vaccine with Merck’s Keytruda outperformed in late-stage study - MSN
IO Biotech shares fall 2.29% premarket after Phase 3 trial results narrowly missed statistical significance. - AInvest
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
IO Biotech sees potential despite cancer vaccine study failure. - AInvest
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma - Seeking Alpha
IO Biotech - The Pharma Letter
IO Biotech Surges 32.9% on Mixed Trial Data: Can Clinical Promise Outpace Regulatory Doubts? - AInvest
IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters
IO Biotech Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Does IO Biotech Inc. meet Warren Buffett’s criteriaFree Profit Target Calculator - thegnnews.com
Io Biotech Inc Stock (IOBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Io Biotech Inc Stock (IOBT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ahmad Qasim Iftikhar | Chief Medical Officer |
Dec 23 '24 |
Buy |
0.85 |
31,350 |
26,553 |
31,350 |
| Zocca Mai-Britt | Chief Executive Officer |
Dec 23 '24 |
Buy |
0.81 |
12,500 |
10,120 |
49,891 |
| Sullivan Amy | Chief Financial Officer |
Dec 23 '24 |
Buy |
0.83 |
10,250 |
8,483 |
84,632 |
| Smith Devin Whittemore | General Counsel |
Dec 23 '24 |
Buy |
0.81 |
12,000 |
9,720 |
16,938 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):